BioSpace News Archive

Elevar Therapeutics, Inc. (“Elevar”), today announced key additions to its senior leadership team with the appointments of experienced industry leaders to several key roles, including Robert Faulkner as vice president (VP) of drug metabolism pharmacokinetics (DMPK).

Evelo Biosciences, Inc., a clinical stage biotechnology company developing SINTAX medicines as a new modality of orally delivered treatments for inflammatory disease, announced positive data from its Phase 2 study evaluating EDP1815 versus placebo for the treatment of mild and moderate psoriasis.

BetterLife Pharma Inc. is pleased to announce it has applied for patent protection of new compositions of 2-bromo-LSD for its use in the treatment of cluster headaches, neuropathic pain and range of mental health conditions, including depression, anxiety and PTSD, and related disorders.

Daré Bioscience, Inc. today announced a Notice of Award of a grant from the Eunice Kennedy Shriver National Institute Of Child Health & Human Development (NICHD) for $309,614.

Nemaura Medical, Inc. announces that it has signed a global commercial contract with MySugarWatch DuoPack Limited (“MSW-DP”).

GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development of GTX-102, an investigational treatment for Angelman syndrome, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold and GeneTx may begin dosing naïve patients in the Phase 1/2 study of GTX-102 in pediatric patients with Angelman syndrome.

Ring Therapeutics today announced that Fierce Biotech has named it as one of 2021’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.

JW Therapeutics (HKEx: 2126), today announced that it has received the Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) of China for a clinical trial of BCMA-targeted Chimeric Antigen Receptor (CAR) T cell JWCAR129 in treating relapsed or refractory multiple myeloma (R/R MM).

Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system therapies, announces that it has closed on a $235 million term loan agreement with Hercules Capital, Inc., a leader in specialty financing for life science and technology companies.

Ortho Clinical Diagnostics, one of the world’s largest pure-play in vitro diagnostics companies, announced the availability of Immediate Spin Crossmatch on the company’s ORTHO VISION® and ORTHO VISION® MAX Analyzers to aid in detecting incompatibility between donors and recipients in blood transfusions.